Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Outline

Abstract
Keywords

Frontiers of Medicine

2020, Volume 14, Issue 6, Pages 701-710

PDF
collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

10.1007/s11684-020-0763-z

Cite this article

Abstract

Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies. Relapse remains the main cause of treatment failure, especially for patients with intermediate or high risk stratification. Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect, which unfortunately puts the patient at risk of serious complications, such as graft-versus-host disease. Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease. In this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords

acute myeloid leukemia ; CAR T ; immunotherapy

Previous article in issue

article in issue Next

Read

Download

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Abstract

Keywords

评论

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Abstract

Keywords

评论

Related Research